Université Libre de Bruxelles

BRACELET-1 study results show improved overall survival (OS) and progression-free survival (PFS) when combining pelareorep with paclitaxel for HR-positive, HER2-negative advanced or metastatic breast cancer patients. The median OS was not reached with pelareorep/paclitaxel vs 18.2 months with paclitaxel alone, and the median PFS was 12.1 months vs 6.4 months. The overall response rate (ORR) was 37.5% with pelareorep/paclitaxel vs 13.3% with paclitaxel alone. These findings support further development of pelareorep in clinical settings.

Prof Andres Cervantes likens ESMO to a tree, providing support and collaboration to oncologists. ESMO offers educational opportunities and embraces emerging trends, including AI and precision medicine. Cervantes emphasizes the importance of better patient outcomes and improved working conditions for oncology professionals, including DEI. ESMO 2024 focused on women's cancers and oncology, with discussions on fertility preservation and sexual health post-cancer treatment. The conference also highlighted advancements in whole genome sequencing and mutational signatures in cancer research.